FANJ
RGNX icon

Financial Architects (New Jersey)’s Regenxbio RGNX Stock Holding History

Financial Architects (New Jersey)’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$38K – 1467
2018
Q3 		$38K Buy
+500
New +$36K 0.01% 725

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Financial Architects (New Jersey)'s RGNX Position: Q4 2018 in Review

Financial Architects (New Jersey) sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 500 shares — an estimated $38K sold.

Financial Architects (New Jersey) first reported a position in RGNX in Q3 2018 and held it in 1 quarter. The position peaked at $38K in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

  • Financial Architects (New Jersey) reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 500 Regenxbio shares in Q4 2018, an estimated $38K.
  • Financial Architects (New Jersey) first reported a position in Regenxbio in Q3 2018 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Regenxbio position peaked at $38K in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2018, filed 1 Feb 2019.